INBX · Inhibrx Biosciences, Inc. · Investor Relations

$95.85 +6.06 (+6.75%)

Russell 2000 member Rebalance outlook locked

Market Cap

$1.32B

14.72M

Volume · Oct 20 41.67K Avg daily vol (3M) 276.09K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-09-08	Earnings conference call (announced in 8-K)	Earnings call
2026-09-08	Inhibrx Presents Phase 2 Randomized Data for INBRX-106 in First-Line HNSCC	Webcast
2026-05-30	2026 American Society of Clinical Oncology (ASCO) Annual Meeting	Shareholder meeting
2026-05-11	Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC	Earnings call
2026-04-21	Earnings conference call (announced in 8-K)	Earnings call
2026-04-21	Inhibrx Biosciences Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer	Webcast
2026-03-12	ESMO Sarcoma and Rare Cancers Congress 2026	Event
2026-02-25	British Sarcoma Group Annual Conference 2026	Conference
2025-11-22	2025 Society for NeuroOncology Annual Meeting	Shareholder meeting
2025-11-14	The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAgon Study	Event
2025-11-05	21st Annual Industry/Academia Precision Oncology & Radmed Symposium	Event
2025-10-23	Inhibrx Announces ozekibart (INBRX-109) Phase 2 results in Chondrosarcoma and Provides Update on CRC and Ewing Cohorts	Earnings call
2025-06-02	2025 American Society of Clinical Oncology (ASCO) Annual Meeting	Shareholder meeting

Source: https://inhibrx.com/inhibrx-biosciences-inc-investors/

Key facts CIK 2007919 CUSIP 45720N103 13F (30d) 12 filings 12 filers Visit website Investor relations